This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
== Classification == The following schema is from the 2015 edition of Vertebrate Palaeontology. The invertebrate chordate classes are from Fishes of the World. While it is generally structured so as to reflect evolutionary relationships (similar to a cladogram), it also retains the traditional ranks used in Linnaean taxonomy.
In selected reaction monitoring, the first analyzer allows only a single mass through and the second analyzer monitors for multiple user-defined fragment ions over longer dwell-times than could be achieved in a full scan. This increases sensitivity. In product ion scans, the first mass analyzer is fixed to select a particular precursor ion ("parent"), while the second is scanned to find all the fragments ("products", or "daughter ions") to which it can be fragmented in the collision cell. In precursor ion scans, the second mass analyzer is fixed to select a particular fragment ion ("daughter"), while the first is scanned to find all possible precursor ions that could give rise to this fragment. In neutral loss scans, the two mass analyzers are scanned in parallel, but separated by the mass of a molecular subunit of interest to the analyst. Ions are detected if they lose that fixed mass during fragmentation. This can be used to look for any chemical that is capable of losing a particular neutral group, for example a sugar residue. Together, neutral loss and precursor ion scans can be used to hunt for chemicals with particular motifs. Another type of tandem mass spectrometry used for radiocarbon dating is accelerator mass spectrometry, which uses very high voltages, usually in the mega-volt range, to accelerate negative ions into a type of tandem mass spectrometer. The METLIN Metabolite and Chemical Entity Database is the largest repository of experimental tandem mass spectrometry data acquired from standards.
=== Surface modification improving stability === Following the formation of porous silicon, its surface is covered with covalently bonded hydrogen. Although the hydrogen coated surface is sufficiently stable when exposed to inert atmosphere for a short period of time, prolonged exposure render the surface prone to oxidation by atmospheric oxygen. The oxidation promotes instability in the surface and is undesirable for many applications. Thus, several methods were developed to promote the surface stability of porous silicon. An approach that can be taken is through thermal oxidation. The process involves heating the silicon to a temperature above 1000 C to promote full oxidation of silicon. The method reportedly produced samples with good stability to aging and electronic surface passivation. Porous silicon exhibits a high degree of biocompatibility. The large surface area enables organic molecules to adhere well. It degrades to Orthosillicic acid (H4SiO4), which causes no harm to the body. This has opened potential applications in medicine such as a framework of the growth of bone.
== Uses == Reduction of sugar intake: G. sylvestre extracts taken in the form of lozenges, mouthwash, or tea diminishes the consumption of sweet foods and overall caloric intake. Extracts (formulated as a mint lozenge) reduced the desire for high-sugar foods and the pleasant taste of candy. Research also suggests that Gymnema sylvestre extracts reduce cravings for sugar. In a double-blind study, participants who received a gymnemic acid lozenge declined candy (before tasting it) more often than the placebo group. Weight loss: In Japan, 50 tons of G. sylvestre leaves are consumed annually for the purpose of weight loss. Early research suggests that taking a specific combination of Gymnema sylvestre extract, hydroxycitric acid, and niacin-bound chromium by mouth for 8 weeks might reduce body weight in people who are overweight or obese. Traditional uses: In Eastern and Ayurvedic medicine, G. sylvestre leaves and extracts have been used to treat eye diseases, allergies, constipation, cough, dental caries, obesity, stomach ailments, and viral infections. G. sylvestre has also been used as an antioxidant, antimicrobial, and aphrodisiac.
Your excellency, Mr President, I greet you in the name of the many thousands of people in Britain who stood against the tide and opposed the war ... I greet you too in the name of the Palestinian people ... I thought the president would appreciate knowing that even today, three years after the war, I still meet families who are calling their newborn sons Saddam ... Sir, I salute your courage, your strength, your indefatigability. And I want you to know that we are with you until victory, until victory, until Jerusalem (hatta al-nasr, hatta al-nasr, hatta al-Quds). During Galloway's 2004 defamation case against the Daily Telegraph, the paper's defence Queen's Counsel accused Galloway of having "fawned over" Saddam during their meeting in 1994. Labour leader John Smith said: "I deeply deplore the foolish statement made in Iraq by Mr. George Galloway. In no way did he speak for the Labour Party and I wholly reject his comments". Galloway said that he was saluting the Iraqi people, rather than Saddam Hussein, and Galloway's friend Anas Altikriti observed that this is how it was translated for Saddam. Shortly after his return, Galloway was given a "severe reprimand" and "final warning" by the Labour Chief Whip, Derek Foster. Galloway apologised for his conduct and undertook to follow future instruction from the whips. For his meeting with Saddam, Galloway was dubbed the "MP for Baghdad North". When he spoke before the U.S.
Sources: en.wikipedia.org
== Transplantation and gene therapy == Hematopoietic stem cells (HSC) are cells in the bone marrow that can develop into all types of blood cells, including red blood cells, white blood cells, and platelets. There are two possible ways to treat hemoglobinopathies by targeting HSCs. One is to transplant HSCs from a healthy donor into the patient's bone marrow; this was pioneered in 1981. More recently, it has become possible to use CRISPR gene editing technology to modify the patient's own HSCs in a way that increases production of functional beta-globin chains, leading to near normal levels of healthy hemoglobin. All stem cell treatments must involve myeloablation of the patients' bone marrow in order to remove HSCs containing the faulty gene. This requires high doses of chemotherapy agents with side effects such as sickness and tiredness. A long hospital stay is necessary after infusion of the replacement HSCs while the cells take up residence in the bone marrow and start to make red blood cells with the stable form of haemoglobin.
acetyl coenzyme A (acetyl-CoA) A biochemical compound consisting of a coenzyme A molecule to which an acetyl group (–COCH3) is attached via a high-energy thioester bond. Acetylation of coenzyme A occurs as part of the metabolism of proteins, carbohydrates (glycolysis), and fatty acids (beta oxidation), after which it participates as an energy carrier in several important biochemical pathways, notably the citric acid cycle, in which hydrolysis of the acetyl group releases energy which is ultimately captured in 11 ATP and one GTP.
A frameshift mutation is caused by insertion or deletion of a number of nucleotides that is not evenly divisible by three from a DNA sequence. Due to the triplet nature of gene expression by codons, the insertion or deletion can disrupt the reading frame, or the grouping of the codons, resulting in a completely different translation from the original. The earlier in the sequence the deletion or insertion occurs, the more altered the protein produced is. (For example, the code CCU GAC UAC CUA codes for the amino acids proline, aspartic acid, tyrosine, and leucine. If the U in CCU was deleted, the resulting sequence would be CCG ACU ACC UAx, which would instead code for proline, threonine, threonine, and part of another amino acid or perhaps a stop codon (where the x stands for the following nucleotide).) By contrast, any insertion or deletion that is evenly divisible by three is termed an in-frame mutation. A point substitution mutation results in a change in a single nucleotide and can be either synonymous or nonsynonymous. A synonymous substitution replaces a codon with another codon that codes for the same amino acid, so that the produced amino acid sequence is not modified. Synonymous mutations occur due to the degenerate nature of the genetic code. If this mutation does not result in any phenotypic effects, then it is called silent, but not all synonymous substitutions are silent.
By the 1930s, Bryant Park was suffering from neglect and was considered disreputable, as the Sixth Avenue elevated literally overshadowed the park. Over a period of 10 years, about 100 separate plans for Bryant Park's renovation were proposed, but never enacted. In an attempt to revitalize the park, the George Washington Bicentennial Planning Committee and Sears filed plans for a replica of Lower Manhattan's Federal Hall in early 1932. During the construction of the replica, part of the park was fenced off. The Dr. Marion Sims and Washington Irving statues were removed; the statues were later found under the Williamsburg Bridge. The replica was opened to the public in May 1932, charging an admission fee for entry. That November, Manhattan parks commissioner Walter R. Herrick formally notified Sears that the replica had to be torn down, because he did not approve of its proposed conversion into a Great Depression relief center. By the next year, the Bicentennial Committee's funds had been exhausted. The replica was torn down in mid-1933. In an attempt to engage unemployed architects, the Architects' Emergency Committee held a competition for the redesign of Bryant Park in 1933. The winning design was submitted by Lusby Simpson, of Queens. However, due to a lack of funding, the winning design was not implemented immediately. In February 1934, under the leadership of newly appointed parks commissioner Robert Moses, work was started on Simpson's plan.
Sources: en.wikipedia.org
== Confession, arrest, and conviction == Wettlaufer entered an inpatient drug rehabilitation program at the Centre for Addiction and Mental Health (CAMH) in Toronto, on September 16, 2016. There, she confessed to CAMH staff about killing or attempting to kill her patients, leading to CAMH notifying the College of Nurses of Ontario (CNO) and the Toronto Police Service. She then emailed CNO to resign as a registered nurse because she had "deliberately harmed patients in [her] care and [was] now being investigated by the police for same", personally called an investigator from CNO, and had CAMH staff fax a four-page handwritten confession. Wettlaufer had confessed to killing patients several times prior to her confession at CAMH, including to a lawyer who advised her to keep it a secret, and was not reported to police. After providing police with a two-hour-long confession, she was formally charged with the eight murders on October 25. After further investigation, she was also charged with four counts of attempted murder and two counts of aggravated assault on January 13, 2017. Wettlaufer waived her right to a preliminary hearing and confessed to all charges in court on June 1. On June 26, she was sentenced to eight concurrent life terms in prison, with no possibility of parole for 25 years. In her confession, Wettlaufer admitted that she "knew the difference between right and wrong" but she was visited by "surges" she could not control. She said, "God or the devil or whatever, wanted me to do it." After one murder, she felt "the surging ...
Aristotle in Outline. Indianapolis: Hackett, 1995. Simondon, Gilbert (2003). L’Individuation à la lumière des notions de forme et d’information [1958]. Paris: Jérôme Millon. Shields, Christopher. "A Fundamental Problem about Hylomorphism". Stanford Encyclopedia of Philosophy. Stanford University. 29 June 2009 <http://plato.stanford.edu/entries/aristotle-psychology/suppl1.html>. Aristotle. London: Routledge, 2007. "Some Recent Approaches to Aristotle's De Anima". De Anima: Books II and III (With Passages From Book I). Trans. W.D. Hamlyn. Oxford: Clarendon, 1993. 157–81. "Soul as Subject in Aristotle's De Anima". Classical Quarterly 38.1 (1988): 140–49. Stump, Eleanore. "Non-Cartesian Substance Dualism and Materialism without Reductionism." Faith and Philosophy 12.4 (October 1995): 505–31. "Resurrection, Reassembly, and Reconstitution: Aquinas on the Soul." Die Menschliche Seele: Brauchen Wir Den Dualismus. Ed. B. Niederbacher and E. Runggaldier. Frankfurt, 2006. 151–72. Vella, John. Aristotle: A Guide for the Perplexed. NY: Continuum, 2008. M.Tiziana Mayer. Menahem da Recanati. Commento alla Genesi: Gn. 1.1-16. Aquilegia Edizioni. Milano, 2005
A newer process, solid oxide membrane technology, involves the electrolytic reduction of MgO. At the cathode, Mg2+ ion is reduced by two electrons to magnesium metal. The electrolyte is yttria-stabilized zirconia (YSZ). The anode is a liquid metal. At the YSZ/liquid metal anode O2− is oxidized. A layer of graphite borders the liquid metal anode, and at this interface carbon and oxygen react to form carbon monoxide. When silver is used as the liquid metal anode, there is no reductant carbon or hydrogen needed, and only oxygen gas is evolved at the anode. It was reported in 2011 that this method provides a 40% reduction in cost per pound over the electrolytic reduction method.
== Mechanism of action == Both dalfopristin and quinupristin bind to sites located on the 50S subunit of the ribosome. Initial dalfopristin binding results in a conformational change of the ribosome, allowing for increased binding by quinupristin. A stable drug-ribosome complex is created when the two drugs are used together. This complex inhibits protein synthesis through prevention of peptide-chain formation and blocking the extrusion of newly formed peptide chains. In many cases, this leads to bacterial cell death.
Hypermobility spectrum disorders (HSD) are a group of heritable connective tissue disorders where joints are flexible enough to cause problems such as instability and pain. Different forms and sub-types have been distinguished, but it does not include asymptomatic joint hypermobility, colloquially known as double-jointedness, nor does it include Ehlers–Danlos syndromes. This condition was called "joint hypermobility syndrome" (JHS) until 2017, when it was renamed and subtypes were defined. There is a strong association between HSD and neurodevelopmental disorders such as attention deficit hyperactivity disorder and autism spectrum disorder.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.